Human Immunoglobulin (pH4) for Intravenous Injection (Zhongke Biopharma)

冻干静注人免疫球蛋白(pH4)（中科生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman Immunoglobulin (pH4) for Intravenous Injection (Zhongke Biopharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Global Approved IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Approved Indications in ChinaX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date2002/08/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBohui Bio-pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBohui Bio-pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ06BA02
Related LinksN/A